Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 16/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228179 | 0.88 | ADRB2 (0.77) | FAAHKDM4EMAPTTSHRSMN1; SMN2 | |
| SCHEMBL8223177 | 0.84 | ADRB2 (0.90) | KDM4ETSHRSMN1; SMN2ADRB2 | |
| SCHEMBL14456716 | 0.84 | ADRB2 (0.59) | FAAHKDM4EMAPTNPC1TSHR | |
| SCHEMBL14456714 | 0.84 | ADRB2 (0.62) | FAAHKDM4EMAPTNPC1TSHR | |
| SCHEMBL8228226 | 0.83 | ADRB2 (0.69) | FAAHTSHRSMN1; SMN2ADRB2 | |
| SCHEMBL14456710 | 0.82 | ADRB2 (0.67) | FAAHTSHRSMN1; SMN2ADRB2 | |
| SCHEMBL3594633 | 0.81 | FAAH (1.00) | FAAHKDM4EMAPTNPC1TSHR | |
| SCHEMBL1942883 | 0.81 | CCR2 (0.65) | FAAHKDM4EMAPTNPC1TSHR | |
| SCHEMBL3596348 | 0.81 | FAAH (1.00) | FAAHKDM4EMAPTNPC1TSHR | |
| SCHEMBL14456711 | 0.80 | ADRB2 (0.65) | FAAHKDM4ETSHRSMN1; SMN2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007075555-A2 | COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-7238688-B2 | Piperidine compounds | SCHERING CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238688-B2 | Piperidine compounds | SCHERING CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | FAAH 15/4885KDM4E 199/4885MAPT 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.